Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

APRE
Aprea Therapeutics, Inc. Common stock
stock NASDAQ

At Close
Jul 18, 2025
1.66USD-0.599%(-0.01)93,479
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 18, 2025 8:00:30 AM EDT
1.73USD+4.217%(+0.07)222
After-hours
Jul 18, 2025 4:56:30 PM EDT
1.71USD0.000%(0.00)896
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 6, 2022
08:00AM EST  Aprea Therapeutics to Present at the 40th Annual J.P. Morgan   GlobeNewswire Inc
Dec 14, 2021
08:22AM EST  Aprea Therapeutics Offers Recap, Update On Data From 3 Presentations In Patients with TP53 Mutant Myelodysplastic Syndromes, Acute Myeloid Leukemia Presented AT American Society Of Hematology Meeting   Benzinga
08:00AM EST  Lead investigators from clinical trials evaluating eprenetapopt in patients withTP53mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting. All studies evaluated the tolerability and efficacy ofAprea Therapeutics, Inc.(Nasdaq: APRE) lead product candidate, eprenetapopt.   GlobeNewswire Inc
Dec 13, 2021
08:10AM EST  Aprea Therapeutics Highlights ASH Presentation Of Primary Analysis From Phase 2 Trial Of Eprenetapopt + Azacitidine   Benzinga
08:00AM EST  -- 60% relapse free survival at 1 year post-transplant -- 79% overall survival at 1 year post-transplant -- Median overall survival of 20.6 months   GlobeNewswire Inc
Dec 9, 2021
09:46PM EST  Aprea Therapeutics Announces Removal Of FDA Clinical Hold On Eprenetapopt In Lymphoid Malignancies   Benzinga
08:51AM EST  Why Aprea Therapeutics Is Rising In Pre-market?   RTTNews
08:21AM EST  Aprea Therapeutics : FDA Removes Clinical Hold On Eprenetapopt In Lymphoid Malignancies; Stock Up   RTTNews
08:00AM EST  Aprea Therapeutics Announces Removal of FDA Clinical Hold on   GlobeNewswire Inc
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Nov 9, 2021
11:11AM EST  Aprea Therapeutics Q3 EPS $(0.45) Up From $(0.58) YoY   Benzinga
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 20, 2021
04:18PM EDT  Aprea Therapeutics Presents Data From Phase 1/2 Trial Of Eprenetapopt In Advanced Solid Tumors At ESMO Congress 2021   Benzinga
04:15PM EDT  Aprea Therapeutics Presents Data From Phase 1/2 Trial of   GlobeNewswire Inc
06:05AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.35 A.M. EDT).   RTTNews
Sep 19, 2021
09:46AM EDT  The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight   Benzinga
Sep 14, 2021
08:03AM EDT  Aprea Therapeutics To Present Data From Phase 1/2 Trial Of Eprenetapopt In Advanced Solid Tumors At ESMO Congress 2021   Benzinga
08:00AM EDT  Aprea Therapeutics to Present Data from Phase 1/2 Trial of   GlobeNewswire Inc
Aug 20, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021   Benzinga
05:15AM EDT  JP Morgan Downgrades Aprea Therapeutics to Underweight   Benzinga
Aug 16, 2021
10:34AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2021   Benzinga
07:31AM EDT  Berenberg Downgrades Aprea Therapeutics to Hold   Benzinga
06:36AM EDT  HC Wainwright & Co. Maintains Neutral on Aprea Therapeutics, Lowers Price Target to $4   Benzinga
Aug 13, 2021
10:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 13, 2021   Benzinga
09:56AM EDT  RBC Capital Maintains Sector Perform on Aprea Therapeutics, Lowers Price Target to $5   Benzinga
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
05:10AM EDT  Morgan Stanley Downgrades Aprea Therapeutics to Underweight, Lowers Price Target to $3   Benzinga
Aug 12, 2021
05:27PM EDT  Aprea Therapeutics Q2 EPS $(0.48) Up From $(0.78) YoY   Benzinga
06:37AM EDT  Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study   Benzinga
06:01AM EDT  Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program   Benzinga
06:00AM EDT  Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy   GlobeNewswire Inc
Aug 9, 2021
08:56AM EDT  RBC Capital Maintains Sector Perform on Aprea Therapeutics, Lowers Price Target to $6   Benzinga
Aug 6, 2021
12:09PM EDT  Aprea Therapeutics shares were trading lower after the company reported a partial clinical hold on myeloid malignancy programs.   Benzinga
08:14AM EDT  Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials   Benzinga
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
05:18PM EDT  Aprea Therapeutics Reports Partial Clinical Hold On Myeloid Malignancy Programs   Benzinga
Jul 21, 2021
10:53AM EDT  Aprea Therapeutics Climbs 3% On Positive Study Results Of   RTTNews
09:19AM EDT  Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant   Benzinga
08:06AM EDT  Aprea Therapeutics Announces Results From Phase 2 Trial Of Eprenetapopt + Azacitidine For Post-Transplant Maintenance Therapy In TP53 Mutant MDS And AML; Results Showed 58% Relapse Free Survival And 79% Overall Survival 1 Year Post Transplant   Benzinga
08:00AM EDT  -- 58% relapse free survival at 1 year post-transplant -- 79% overall survival at 1 year post-transplant   GlobeNewswire Inc
Jun 16, 2021
02:32PM EDT  Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Federal Reserve Maintains Interest Rates   Benzinga
12:03PM EDT  Mid-Day Market Update: Dow Falls 40 Points; Aprea Therapeutics Shares Surge   Benzinga
10:17AM EDT  Mid-Morning Market Update: Markets Mixed; Elanco Animal Health To Acquire Kindred Biosciences   Benzinga
09:24AM EDT  Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients   Benzinga
08:54AM EDT  Aprea Therapeutics Inc. (APRE) said that the phase 1/2 trial, which evaluated the frontline treatment of eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant acute myeloid leukemia or AML, has met the pre-specified primary efficacy endpoint of complete remission or CR rate.   RTTNews
08:15AM EDT  Aprea: Phase 1/2 Trial Of Eprenetapopt + Venetoclax + Azacitidine Meets Complete Remission Primary Efficacy Endpoint   RTTNews
08:02AM EDT  Aprea Therapeutics Announces Phase 1/2 Trial Of Eprenetapopt + Venetoclax + Azacitidine In TP53 Mutant AML Met Complete Remission Primary Efficacy Endpoint   Benzinga
08:00AM EDT  Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt +   GlobeNewswire Inc
May 21, 2021
06:00AM EDT  Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare &   GlobeNewswire Inc
May 18, 2021
06:00AM EDT  Aprea Therapeutics to Participate in the 2021 RBC Capital Markets   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
05:36PM EDT  Aprea Therapeutics Q1 EPS $(0.46) Down From $(0.45) YoY   Benzinga
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 16, 2021
09:15AM EDT  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that it will host a virtual R&D Day at 1:00 p.m. ET on Thursday, April 22, 2021.   GlobeNewswire Inc
08:01AM EDT  The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs   Benzinga
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Apr 8, 2021
11:15AM EDT  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to eprenetapopt for treatment of AML.   GlobeNewswire Inc
06:02AM EDT  Aprea Therapeutics on Wednesday Received FDA Orphan Drug Designation for eprenetapopt for Treatment of Acute Myeloid Leukemia   Benzinga
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 17, 2021
07:49AM EDT  RBC Capital Maintains Sector Perform on Aprea Therapeutics, Lowers Price Target to $8   Benzinga
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
Mar 16, 2021
04:22PM EDT  Aprea Therapeutics Q4 EPS $(0.73) Down From $(0.64) YoY   Benzinga
04:15PM EDT  Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months and year endedDecember 31, 2020and provided a business update.   GlobeNewswire Inc
Jan 8, 2021
08:00AM EST  Aprea Therapeutics to Present at the 39th Annual J.P. Morgan   GlobeNewswire Inc
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Dec 30, 2020
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 29, 2020
10:12AM EST  Benzinga's Top Upgrades, Downgrades For December 29, 2020   Benzinga
09:11AM EST  7 Biggest Price Target Changes For Tuesday   Benzinga
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
06:29AM EST  RBC Capital Downgrades Aprea Therapeutics to Sector Perform, Lowers Price Target to $10   Benzinga
Dec 28, 2020
02:31PM EST  Mid-Afternoon Market Update: Nasdaq Jumps Over 100 Points; AeroCentury Shares Spike Higher   Benzinga
01:57PM EST  Mid-Day Market Update: Dow Surges 240 Points; Aprea Therapeutics Shares Plunge   Benzinga
10:21AM EST  Mid-Morning Market Update: Markets Open Higher; President Trump Signs $900B Covid-19 Relief Bill   Benzinga
10:03AM EST  Shares of Aprea Therapeutics Inc. (APRE) are currently plunging nearly 80% after the biopharmaceutical company focused on cancer therapy said a late-stage trial of blood cancer drug failed to meet primary endpoint.   RTTNews
08:07AM EST  Aprea Shares To Resume Trade At 8:30 a.m. EST   Benzinga
08:00AM EST  Aprea Therapeutics Reports Phase 3 Trial Of Eprenetapopt In TP53 Mutant Myelodysplastic Syndromes Failed To Meet Primary Endpoint   Benzinga
08:00AM EST  -- The trial failed to meet its primary endpoint of complete remission (CR) rate -- CR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance   GlobeNewswire Inc
07:59AM EST  Aprea Therapeutics Shares Halted News Pending   Benzinga
Dec 26, 2020
09:16AM EST  The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks   Benzinga
Dec 16, 2020
12:17PM EST  Morgan Stanley Maintains Equal-Weight on Aprea Therapeutics, Lowers Price Target to $34   Benzinga
11:25AM EST  Benzinga's Top Upgrades, Downgrades For December 16, 2020   Benzinga
10:26AM EST  Berenberg Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $37   Benzinga
Nov 30, 2020
08:05AM EST  Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia   Benzinga
08:00AM EST  Aprea Therapeutics Receives FDA Fast Track Designation for   GlobeNewswire Inc
Nov 19, 2020
08:00AM EST  Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler   GlobeNewswire Inc
Nov 6, 2020
02:45PM EST  Stocks Trading Near 52-Week Lows On Friday, Nov. 6, 2020: ASRT, KBLMU, PNRG, YGMZ, APRE, UHT, LAIX, CLI, CORR, ANIP, CCOI, KBLM, NYC, UTL, PEI, TIG, EYEG, PVL, ZSAN, TTNP, NBRV, SFT, WPG, IFS, COGT, LMNL, PRFX, GBT, FNHC, ASMB, EPZM, UCL   Benzinga
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Nov 5, 2020
05:46PM EST  Aprea Therapeutics Q3 EPS $(0.58) Up From $(5.29) YoY   Benzinga
Nov 4, 2020
08:21AM EST  The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings   Benzinga
Oct 30, 2020
04:00AM EDT  Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, will host a live virtual R&D Day Webinar, with presentations by key opinion leaders in hematology, today from 1:00 3:00 pm Eastern Time.   GlobeNewswire Inc
Oct 14, 2020
08:00AM EDT  Aprea Therapeutics Launches Disease Awareness Website for   GlobeNewswire Inc
Oct 7, 2020
08:02AM EDT  Aprea Therapeutics Receives FDA Approval to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548   Benzinga
08:00AM EDT  Aprea Therapeutics Receives OK from FDA to Initiate Phase 1   GlobeNewswire Inc
Sep 29, 2020
08:00AM EDT  Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors   GlobeNewswire Inc
Sep 18, 2020
08:06AM EDT  Aprea Therapeutics Promotes Gregory Wessels To Chief Commercial Officer   RTTNews
08:00AM EDT  Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the promotion of Gregory S. Wessels to the newly created position of Chief Commercial Officer.   GlobeNewswire Inc
Sep 3, 2020
08:01AM EDT  Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the Company is scheduled to present at two upcoming healthcare investor conferences:   GlobeNewswire Inc
Aug 11, 2020
04:28PM EDT  Aprea Therapeutics Q2 EPS $(0.78) Up From $(4.45) YoY   Benzinga
04:15PM EDT  Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three and six months endedJune 30, 2020and provided a business update.   GlobeNewswire Inc
Jul 16, 2020
07:15AM EDT  Aprea Therapeutics Reports Expansion Of Clinical Trial Evaluating Eprenetapopt For Front-Line Treatment Of TP53 Mutant Acute Myeloid Leukemia   Benzinga
07:00AM EDT  -- Commenced expansion cohort in combination with venetoclax and azacitidine -- Added cohort to be activated in combination with azacitidine   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC